

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**84902**

**CHEMISTRY REVIEW(S)**

CHEMIST'S REVIEW FOR  
ABBREVIATED NEW DRUG APPLICATION  
OR SUPPLEMENT

Statement Date:

NDA #

84-902

NAME AND ADDRESS OF APPLICANT:

Alcon Laboratories, Inc.  
Fort Worth, TX 76101

ORIGINAL  
AMENDMENT XXX  
SUPPLEMENT  
RESUBMISSION  
CORRESPONDENCE  
REPORT  
OTHER

PURPOSE OF AMENDMENT/SUPPLEMENT

Bioavailability data

DATE(s) of SUBMISSION(s)

9-3-80; 6-25-81

PHARMACOLOGICAL CATEGORY

antihistamine

NAME OF DRUG

Promethacon (promethazine HCl)

HOW DISPENSED

RX xxxx OTC       

DOSAGE FORM

suppository

POTENCY(IES)

50 mg.

RELATED IND/NDA/DMF

STERILIZATION

N.A.

SAMPLES

validated

LABELING

FPL satisfactory per Dr. Seife 10-1-81

BIOLOGIC AVAILABILITY

Satisfactory per Dr. Pelsor review 6-25-81

ESTABLISHMENT INSPECTION

Satisfactory per 7-17-81

COMPONENTS, COMPOSITION, MANUFACTURING, CONTROLS

Previously reviewed by J. Taylor 2-19-76.

PACKAGING

Satisfactory

STABILITY:

Protocol:

Nine months data at 35°C shows product is stable. Room temperature data  
submitted for 6-9 months then skips to 36 months. All 36 month data  
slightly less than 90% of label by USP method. method  
consistently higher % than USP assay.

Exp. Date:

Propose two years.

REMARKS & CONCLUSION:

approval

REJoyce 10-1-81

FEDERAL BUREAU OF INVESTIGATION  
NEW DRUG APPLICATION  
OR SUPPLEMENT

RECEIVED REGISTERED  
Statement Date

INDA NUMBER **84-902**

File Number **77-736**

Name and Address of Applicant (City and State)

**Alcon Laboratories, Inc.  
Mfg. Bureau, MA**

Original \_\_\_\_\_  
Amendment **XX** \_\_\_\_\_  
Supplement \_\_\_\_\_  
Resubmission \_\_\_\_\_  
Correspondence \_\_\_\_\_  
Report \_\_\_\_\_  
Other \_\_\_\_\_

Purpose of Amendment/Supplement

**Labeling, stability**

Date(s) of Submission(s)

**12-5, 15, 1976**

Pharmacological Category

**antibiotic**

Trade Name of Drug

**Doxothiazine HCl**

Usage Form(s)

**suppository**

Potency(ies)

**25 mg. 50 mg.**

How Dispensed

**XXX**

OTC

Packaging/Sterilization

**Foil pouch/MA**

Samples

**Received--not yet sent**

Related IND/NDA/NS

**84-902 25 mg.  
84-902 50 mg.**

Labeling

**Satisfactory for container. (JHerry) Insert may require revision if bio study so indicates**

Biologic Availability

**Required per current ruling--source memo of 12-5 meeting**

Establishment Inspection

**Satisfactory**

Components, Composition, Manufacturing and Controls

**Satisfactory at present--if bio indicates a particular chemical test would help insure bioavailability reproducibility additional tests will be required at that time.**

Remarks

**Request 72L container  
Bio required**

**BEST POSSIBLE COPY**

Application

**Res w/f**

**2-17-76**

FILED

Name and Address of Applicant (City and State)

**Alcon Laboratories, Inc.  
Ft. Worth, TX 76101**

Original \_\_\_\_\_  
Amendment **XX** \_\_\_\_\_  
Supplement \_\_\_\_\_  
Resubmission \_\_\_\_\_  
Correspondance \_\_\_\_\_  
Report \_\_\_\_\_  
Other \_\_\_\_\_

Purpose of Amendment/Supplement

**Stability data preliminary**

Date(s) of Submission(s)

**October 7, 1975**

Pharmacological Category

**antihistamine**

Name of Drug

**Fenethasine Hydrochloride**

Dosage Form(s)

**Suppository**

Potency(ies)

~~85 mg.~~  
**50 mg.**

How Dispensed

~~Rx only~~  
**X**

OTC

Packaging/Sterilization

**Foil/PB**

Samples

**requested**

Related IND/NDA/ME

**84-901 25 mg.  
84-902 50 mg.**

Labeling

**See previous review**

Biologic Availability

**Not required at present, no additional clinical data required  
(Meife)**

Establishment Inspection

**Satisfactory**

Components, Composition, Manufacturing and Controls

**See previous review**

Remarks

**Request information as before. Acknowledge stability commitment.**

Conclusion

*Rev w/f*

*ISI*

*10-20-75*

CHEMIST'S REVIEW FOR  
ABBREVIATED NEW DRUG APPLICATION  
OR SUPPLEMENT

Federal Register  
Statement Date

6/18/71

ANDA Number 84-902

AF Number 27-736

Name and Address of Applicant (City and State)

Alcon Laboratories, Inc.  
Ft. Worth, TX 76101

Original xx  
Amendment \_\_\_\_\_  
Supplement \_\_\_\_\_  
Resubmission \_\_\_\_\_  
Correspondance \_\_\_\_\_  
Report \_\_\_\_\_  
Other \_\_\_\_\_

Purpose of Amendment/Supplement

Date(s) of Submission(s)  
September 9, 1975

Pharmacological Category

antihistamine

Name of Drug

Promethacon Suppettes  
Promethazine Hydrochloride

Dosage Form(s)

suppository

Potency (ies)

50 mg.

How Dispensed

~~RX~~  
X

OTC

Packaging/Sterilization

Foil/polyester/PE  
next to drug heat seal

Samples

Requested *gr*  
~~Not required~~

Related IND/NDA/NF

84-901 25 mg.

Labeling

Satisfactory (JRCarr)

Biologic Availability

Deferred

Establishment Inspection

Requested

Components, Composition, Manufacturing and Controls

Satisfactory per application

Remarks

1. FPL of insert/carton.
2. Proposed immediate container labeling.
3. Composition of the coloring agent--

Conclusion

*RW w/A*

REVIEWER

DATE

*9-23-75*